Kamil Pohlodek

Has grant

Professor of OB/GYN (Full)

Comenius University in Bratislava
Country flagSlovakia

Research Interests

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Explore related searches

Recent Grants

Grant: Close

Clinical evaluation of prognostic and predictive value of tissue and serum Carbonic Anhydrase IX in breast cancer

Open Date: 2019-11-01

Close Date: 2022-10-01

Grant: Close

The role of carbonic anhydrase IX in tumor metabolism: Control of function and clinical impact.

Open Date: 2015-01-01

Close Date: 2018-12-01

Grant: Close

Disseminated tumor cells in bone marrow in breast cancer patients

Open Date: 2008-09-01

Close Date: 2010-10-01

Grant: Close

LIBERATE : a multinational, multicenter, randomized, double-blind, parallel-group, placebo-controlled trial to investigate safety and efficacy of tibolone in women with climacteric symptoms and a history of breast cancer.

Open Date: 2002-02-01

Close Date: 2026-10-01

Grant: Close

An exploratory, double-blind, randomized, placebo-controlled trial to investigate the tissue-specific effects of 2,5 mg tibolone on breast cancer in postmenopausal women, in particular on breast tissue proliferation.

Open Date: 2002-01-01

Close Date: 2006-08-01

Articles (6)

Year:

2025

Carbonic anhydrase IX (CA IX) is recognized as an excellent marker of hypoxia and an adverse prognostic factor in solid tumors, including breast cancer (BC). Clinical studies confirm that soluble CA IX (sCA IX), shed into body fluids, predicts the response to some therapeutics. However, CA IX is not included in clinical practice guidelines, possibly due to a lack of validated diagnostic tools. Here, we present two novel diagnostic tools—a monoclonal antibody for CA IX detection by immunohistochemistry and an ELISA kit for the detection of sCA IX in the plasma—validated on a cohort of 100 patients with early BC. We confirm that tissue CA IX positivity (24%) correlates with tumor grading, necrosis, negative hormone receptor status, and the TNBC molecular subtype. We show that antibody IV/18 can specifically detect all subcellular forms of CA IX. Our ELISA test provides 70% sensitivity and 90% specificity. Although we showed that this test could detect exosomes in addition to shed CA IX ectodomain, we could not demonstrate a clear association of sCA IX with prognosis. Our results indicate that the amount of sCA IX depends on subcellular CA IX localization, but more strictly on the molecular composition of individual molecular subtypes of BC, particularly on metalloproteinases inhibitor expression.

Year:

2023

Year:

2023

Year:

2023

Year:

2020

Year:

2020